PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
12522097-4	2003	3 The NK(1) receptor antagonist CP99994 (1 microM, n=9) blocked 93% of the SP-induced J(G), whereas the NK(3) receptor antagonist SB223412 (1 microM, n=12) had no effect on the SP-induced J(G).	3-(2-methoxybenzylamino)-2-phenylpiperidine	32-39	tachykinin receptor 1	Homo sapiens	6-20
15501529-4	2004	Eledoisin (NK3 preferring in mammals) stimulation of SCC is reduced by CP99994 and SR48968 (NK1 and NK2 antagonists) and not affected by SB222200 (NK3 antagonist).	3-(2-methoxybenzylamino)-2-phenylpiperidine	71-78	NK3 homeobox 1	Homo sapiens	11-14
14565542-4	2003	In the isolated bronchi, the tachykinin NK1-receptor antagonist CP 99994 (0.01-1 microM) produced concentration-dependent inhibition of contractions induced the tachykinin NK1-receptor agonists substance P (SP) and [Met-OMe11] SP ([Met-OMe11]SP), whereas the tachykinin NK2-receptor antagonist SR 48968 (0.1 microM) had no effect.	3-(2-methoxybenzylamino)-2-phenylpiperidine	64-72	substance-K receptor	Cavia porcellus	270-282
12376343-7	2002	Pretreatment with CP-99994, an antagonist of neurokinin 1 receptor, attenuated the IL-1beta-induced hyperreactivity to ACh and MCh and to EFS in cultured tracheal segments.	3-(2-methoxybenzylamino)-2-phenylpiperidine	18-26	interleukin-1 beta	Mustela putorius furo	83-91
12376343-7	2002	Pretreatment with CP-99994, an antagonist of neurokinin 1 receptor, attenuated the IL-1beta-induced hyperreactivity to ACh and MCh and to EFS in cultured tracheal segments.	3-(2-methoxybenzylamino)-2-phenylpiperidine	18-26	embryonal Fyn-associated substrate	Mustela putorius furo	138-141
12388658-9	2002	The combination of gabapentin with a structurally unrelated NK(1) receptor antagonist, (2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994), also produced synergy, at a fixed dose ratio of 20:1.	3-(2-methoxybenzylamino)-2-phenylpiperidine	87-138	tachykinin receptor 1	Rattus norvegicus	60-74
12372027-4	2002	This baroreceptor reflex depression was mimicked by NTS microinjection of substance P and antagonized by microinjection of either bicuculline (a GABAA receptor antagonist) or a neurokinin type 1 (NK1) receptor antagonist (CP-99994).	3-(2-methoxybenzylamino)-2-phenylpiperidine	222-230	tachykinin receptor 1	Rattus norvegicus	177-209
11266378-7	2001	Mobilization of the receptor by SP was blocked by the NK(1)-receptor antagonist CP99994.	3-(2-methoxybenzylamino)-2-phenylpiperidine	80-87	substance-P receptor	Cavia porcellus	54-68
12059053-6	2002	Infusion of the NK1 receptor antagonist CP99994 (10(-6) M) during continued atropine infusion blocked net aboral propulsive complexes in 5 experiments for 12.2 +/- 2.4 min and resulted in motor paralysis in 2 experiments.	3-(2-methoxybenzylamino)-2-phenylpiperidine	40-47	tachykinin receptor 1	Homo sapiens	16-28
11698156-4	2001	In AP ablated animals the selective NK(1) receptor antagonist CP-99, 994 (1 mg kg(-1) i.v.)	3-(2-methoxybenzylamino)-2-phenylpiperidine	62-72	tachykinin receptor 1	Canis lupus familiaris	36-50
11427331-4	2001	The action of substance P to increase the evoked release of glutamate was blocked by the antagonist CP-99994, suggesting a specific involvement of the NK(1) receptor in mediating the facilitatory effect.	3-(2-methoxybenzylamino)-2-phenylpiperidine	100-108	tachykinin receptor 1	Rattus norvegicus	151-165
10562347-12	1999	The neurokinin type 1 (NK1) receptor antagonist CP-99,994 (5 microM) blocked the ANGII-induced increase in EPSPs but had no effect on TS-evoked IPSP potentiation by ANGII.	3-(2-methoxybenzylamino)-2-phenylpiperidine	48-57	tachykinin receptor 1	Rattus norvegicus	4-36
10840459-5	2000	IP injection of the NK1 receptor antagonist CP 99994 (10 mg./kg.	3-(2-methoxybenzylamino)-2-phenylpiperidine	44-52	substance-P receptor	Cavia porcellus	20-32
11041273-8	2000	The selective tachykinin NK1 antagonist, CP 94, 994 [(+/-)-(2S, 3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine], also partially attenuated both the scratching (64%) and the head-twitching (76%) symptoms produced by SR 141716A.	3-(2-methoxybenzylamino)-2-phenylpiperidine	53-111	killer cell lectin-like receptor subfamily B member 1C	Mus musculus	25-28
10604965-6	2000	The relaxations to SP, NKA, and ASM-SP were competitively antagonized by the selective NK-1 receptor antagonist CP 99994, with a pK(b) in the nanomolar range.	3-(2-methoxybenzylamino)-2-phenylpiperidine	112-120	tachykinin precursor 1	Homo sapiens	23-26
10604965-6	2000	The relaxations to SP, NKA, and ASM-SP were competitively antagonized by the selective NK-1 receptor antagonist CP 99994, with a pK(b) in the nanomolar range.	3-(2-methoxybenzylamino)-2-phenylpiperidine	112-120	tachykinin receptor 1	Homo sapiens	87-100
10996469-6	2000	The NK(1) receptor endocytosis was reduced by the selective NK(1) receptor antagonist, CP-99994 (100 nM), but not by the selective NK(3) receptor antagonist, SR-142801 (1 microM).	3-(2-methoxybenzylamino)-2-phenylpiperidine	87-95	tachykinin receptor 1	Rattus norvegicus	4-18
10996469-6	2000	The NK(1) receptor endocytosis was reduced by the selective NK(1) receptor antagonist, CP-99994 (100 nM), but not by the selective NK(3) receptor antagonist, SR-142801 (1 microM).	3-(2-methoxybenzylamino)-2-phenylpiperidine	87-95	tachykinin receptor 1	Rattus norvegicus	60-74
10900217-4	2000	Two chemically unrelated NK(1) receptor antagonists, CP-99,994 (3-30 mg/kg) and SR 140333 (1-100 mg/kg), also dose dependently blocked the late phase, with respective MEDs of 3 and 10 mg/kg.	3-(2-methoxybenzylamino)-2-phenylpiperidine	53-62	tachykinin receptor 1	Rattus norvegicus	25-39
10562347-12	1999	The neurokinin type 1 (NK1) receptor antagonist CP-99,994 (5 microM) blocked the ANGII-induced increase in EPSPs but had no effect on TS-evoked IPSP potentiation by ANGII.	3-(2-methoxybenzylamino)-2-phenylpiperidine	48-57	angiotensinogen	Rattus norvegicus	81-86
10502070-4	1999	Binding to NK(1) receptors was blocked by the NK(1) receptor antagonist, CP-99994.	3-(2-methoxybenzylamino)-2-phenylpiperidine	73-81	substance-P receptor	Cavia porcellus	11-25
10366753-2	1999	These actions were completely blocked by substance P (NK1) receptor antagonists, such as CP-96345 and CP-99994, but not by their inactive derivatives, CP-96344 or CP-100263, nor by MEN-10376, an NK2 antagonist.	3-(2-methoxybenzylamino)-2-phenylpiperidine	102-110	tachykinin precursor 1	Homo sapiens	41-52
10454146-4	1999	In addition, the intraplantar application of CP-99994 (1 pmol), a substance P (NK1) receptor antagonist, but not CP-100263 (1 pmol), an inactive derivative, also markedly reduced the LPA responses.	3-(2-methoxybenzylamino)-2-phenylpiperidine	45-53	tachykinin 1	Mus musculus	66-77
10454146-4	1999	In addition, the intraplantar application of CP-99994 (1 pmol), a substance P (NK1) receptor antagonist, but not CP-100263 (1 pmol), an inactive derivative, also markedly reduced the LPA responses.	3-(2-methoxybenzylamino)-2-phenylpiperidine	45-53	tachykinin receptor 1	Mus musculus	79-92
10366753-2	1999	These actions were completely blocked by substance P (NK1) receptor antagonists, such as CP-96345 and CP-99994, but not by their inactive derivatives, CP-96344 or CP-100263, nor by MEN-10376, an NK2 antagonist.	3-(2-methoxybenzylamino)-2-phenylpiperidine	102-110	tachykinin receptor 1	Homo sapiens	54-67
9676748-5	1998	Substance P could be excluded as inhibitory transmitter because the effect of SIN-1 remained unchanged in the presence of the NK1 receptor antagonist CP 99994 (100 nM).	3-(2-methoxybenzylamino)-2-phenylpiperidine	150-158	substance-P receptor	Cavia porcellus	126-138
10657468-7	1999	CP 99994 (1 microM), a NK(1)-receptor antagonist, was inactive against NKA responses in all three species.	3-(2-methoxybenzylamino)-2-phenylpiperidine	0-8	tachykinin receptor 1	Homo sapiens	23-37
9808699-7	1998	VO2 stimulation was significantly inhibited (P <.05) by the selective NK1 receptor antagonist CP-99994 (1 microM) and the NK2 receptor antagonist SR 48968 (1 microM) (by 42% and 51%, respectively), but PP was not altered.	3-(2-methoxybenzylamino)-2-phenylpiperidine	97-105	tachykinin receptor 1	Rattus norvegicus	73-85
9832399-4	1998	The non-peptide NK1 receptor antagonist, CP 99,994 ((2S,3S)-3-(2-methoxybenzyl)amino-2-phenylpiperidine), caused a dextral shift of the first sigmoidal response, indicating the involvement of an NK1 receptor.	3-(2-methoxybenzylamino)-2-phenylpiperidine	41-50	tachykinin receptor 1	Homo sapiens	16-28
9832399-4	1998	The non-peptide NK1 receptor antagonist, CP 99,994 ((2S,3S)-3-(2-methoxybenzyl)amino-2-phenylpiperidine), caused a dextral shift of the first sigmoidal response, indicating the involvement of an NK1 receptor.	3-(2-methoxybenzylamino)-2-phenylpiperidine	41-50	tachykinin receptor 1	Homo sapiens	195-207
9832399-4	1998	The non-peptide NK1 receptor antagonist, CP 99,994 ((2S,3S)-3-(2-methoxybenzyl)amino-2-phenylpiperidine), caused a dextral shift of the first sigmoidal response, indicating the involvement of an NK1 receptor.	3-(2-methoxybenzylamino)-2-phenylpiperidine	52-103	tachykinin receptor 1	Homo sapiens	16-28
9832399-4	1998	The non-peptide NK1 receptor antagonist, CP 99,994 ((2S,3S)-3-(2-methoxybenzyl)amino-2-phenylpiperidine), caused a dextral shift of the first sigmoidal response, indicating the involvement of an NK1 receptor.	3-(2-methoxybenzylamino)-2-phenylpiperidine	52-103	tachykinin receptor 1	Homo sapiens	195-207
9832399-6	1998	Increasing concentrations of CP 99,994 (0.1, 0.3 and 1 microM) produced a parallel dextral shift of the [Sar9Met(O2)11]substance P curve with a slope of the Schild regression significantly different from unity (1.59).	3-(2-methoxybenzylamino)-2-phenylpiperidine	29-38	tachykinin precursor 1	Homo sapiens	119-130
9711352-9	1998	An antagonist of NK1 receptors for tachykinins, CP 99,994, inhibited the physalaemin action on SCC, whereas challenge with SR 48,968, an antagonist of NK2 receptors, had no effect on physalaemin action.	3-(2-methoxybenzylamino)-2-phenylpiperidine	48-57	tachykinin receptor 1	Homo sapiens	17-20
9641542-7	1998	Pretreatment of sensitized guinea-pigs with the NK1 receptor antagonists CP99994 (4 mg kg(-1), i.p.	3-(2-methoxybenzylamino)-2-phenylpiperidine	73-80	substance-P receptor	Cavia porcellus	48-60
9641542-15	1998	Pretreatment with the NK1 receptor antagonists CP99994 or SR140333 before challenge prevented this increase.	3-(2-methoxybenzylamino)-2-phenylpiperidine	47-54	substance-P receptor	Cavia porcellus	22-34
9658033-4	1998	The SP-induced prolongation of NMDA channel openings is prevented by the selective NK-1 receptor antagonist (+)-(2S, 3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994).	3-(2-methoxybenzylamino)-2-phenylpiperidine	108-164	tachykinin receptor 1	Rattus norvegicus	83-96
9658033-4	1998	The SP-induced prolongation of NMDA channel openings is prevented by the selective NK-1 receptor antagonist (+)-(2S, 3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994).	3-(2-methoxybenzylamino)-2-phenylpiperidine	166-175	tachykinin receptor 1	Rattus norvegicus	83-96
9466466-4	1998	In addition, ODQ (1 microM) increased the electrically-evoked tachykininergic and cholinergic muscle contractions as measured in the presence of scopolamine (100 nM) or of the neurokinin-1 receptor antagonist CP 99994 (100 nM), respectively.	3-(2-methoxybenzylamino)-2-phenylpiperidine	209-217	substance-P receptor	Cavia porcellus	176-197
9366060-6	1997	The neurokinin-1 antagonist, CP 99,994, did not alter the response to histamine (0.1 mM).	3-(2-methoxybenzylamino)-2-phenylpiperidine	29-38	tachykinin precursor 1	Homo sapiens	4-16
9353399-10	1997	Pretreatment with the NK1-receptor antagonist, CP 99994 (1 mg/kg, i. v.) had no effect on the increase in lung resistance and the decrease in dynamic lung compliance due to NKA challenge, but blunted the respiratory response to NKA.	3-(2-methoxybenzylamino)-2-phenylpiperidine	47-55	tachykinin receptor 1	Canis lupus familiaris	22-34
9353399-10	1997	Pretreatment with the NK1-receptor antagonist, CP 99994 (1 mg/kg, i. v.) had no effect on the increase in lung resistance and the decrease in dynamic lung compliance due to NKA challenge, but blunted the respiratory response to NKA.	3-(2-methoxybenzylamino)-2-phenylpiperidine	47-55	tachykinin precursor 1	Homo sapiens	228-231
9117085-2	1997	The NK1 receptor antagonist CP-99994 has been shown to prevent vomiting elicited by both peripherally and centrally acting emetogens in ferrets and dogs.	3-(2-methoxybenzylamino)-2-phenylpiperidine	28-36	tachykinin receptor 1	Homo sapiens	4-7
9190858-7	1997	The more potent inhibitor of [3H] SP binding, (+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994), was approximately 10 times more potent in inhibiting NMDA-induced activity than CP-96,345.	3-(2-methoxybenzylamino)-2-phenylpiperidine	46-101	tachykinin 1	Mus musculus	34-36
9117085-9	1997	The antiemetic effect of CP-99994 can be attributed to antagonism of the NK1 receptor because its enantiomer, CP-100,263, which is 900 fold weaker as an NK1 antagonist, had no effects on any response to provocative motion.	3-(2-methoxybenzylamino)-2-phenylpiperidine	25-33	tachykinin receptor 1	Homo sapiens	73-85
9117085-9	1997	The antiemetic effect of CP-99994 can be attributed to antagonism of the NK1 receptor because its enantiomer, CP-100,263, which is 900 fold weaker as an NK1 antagonist, had no effects on any response to provocative motion.	3-(2-methoxybenzylamino)-2-phenylpiperidine	25-33	tachykinin receptor 1	Homo sapiens	73-76
7543746-7	1995	The first clinical trial with FK224, a peptide NK1 and NK2 receptor antagonist, and CP99994, a nonpeptide NK1 receptor antagonist, are negative.	3-(2-methoxybenzylamino)-2-phenylpiperidine	84-91	tachykinin receptor 1	Homo sapiens	106-118
9227843-4	1997	Pretreatment of morphine-dependent rats with an intrathecal injection of 100 nmol of the neurokinin-1 receptor antagonist CP-99994 significantly inhibited the magnitude and shortened the duration of the pressor response to naloxone.	3-(2-methoxybenzylamino)-2-phenylpiperidine	122-130	tachykinin receptor 1	Rattus norvegicus	89-110
8864563-7	1996	Capsaicin-induced hyperalgesia was prevented and reversed by the NK1 receptor antagonists CP 99994 (100 nmol) and RP 67580 (1 nmol).	3-(2-methoxybenzylamino)-2-phenylpiperidine	90-98	tachykinin receptor 1	Rattus norvegicus	65-77
7659444-3	1995	In mice, the NK1 antagonist, CP 99,994, preferentially (inhibitory dose50 (ID50) = 4.4) inhibited the late phase (LP) as compared to the early phase (EP) (16.1) of formalin-induced licking (FIL).	3-(2-methoxybenzylamino)-2-phenylpiperidine	29-38	tachykinin 1	Mus musculus	13-16
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	tachykinin receptor 1	Mus musculus	51-55
7541093-0	1995	Effects of CP-99,994, an NK1-receptor antagonist, on the inward current produced by substance P.	3-(2-methoxybenzylamino)-2-phenylpiperidine	11-20	tachykinin receptor 1	Homo sapiens	25-37
7541093-0	1995	Effects of CP-99,994, an NK1-receptor antagonist, on the inward current produced by substance P.	3-(2-methoxybenzylamino)-2-phenylpiperidine	11-20	tachykinin precursor 1	Homo sapiens	84-95
7687598-4	1993	The natural agonist of NK1 receptors, substance P (1 micrograms/kg), increased airway blood flow, an effect that was abolished by the selective NK1 receptor antagonist CP-99,994 [(+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine] but not by the (2R,3R)-enantiomer CP-100,263.	3-(2-methoxybenzylamino)-2-phenylpiperidine	179-234	tachykinin receptor 1	Rattus norvegicus	23-35
7682613-4	1993	The natural agonist of NK1 receptors, substance P (1 microgram/kg), increased nasal blood flow, an effect that was abolished by the selective NK1 receptor antagonist (+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994).	3-(2-methoxybenzylamino)-2-phenylpiperidine	166-221	tachykinin receptor 1	Rattus norvegicus	23-35
7682613-4	1993	The natural agonist of NK1 receptors, substance P (1 microgram/kg), increased nasal blood flow, an effect that was abolished by the selective NK1 receptor antagonist (+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994).	3-(2-methoxybenzylamino)-2-phenylpiperidine	223-232	tachykinin receptor 1	Rattus norvegicus	23-35
32956833-12	2021	In addition, the discharge rates of spinal wide dynamic response (WDR) neurons significantly increased following SP or acupuncture treatment in Neuro-Sps in normal rats, but decreased following the injection of CP-99994 into Neuro-Sps in IMH rats.	3-(2-methoxybenzylamino)-2-phenylpiperidine	211-219	trefoil factor 2	Rattus norvegicus	113-115
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	tumor necrosis factor	Mus musculus	116-143
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	tumor necrosis factor	Mus musculus	145-154
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	interleukin 1 beta	Mus musculus	157-175
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	interleukin 1 alpha	Mus musculus	177-185
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	interleukin 6	Mus musculus	188-192
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	nitric oxide synthase 2, inducible	Mus musculus	194-241
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	nitric oxide synthase 2, inducible	Mus musculus	243-247
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	prostaglandin-endoperoxide synthase 2	Mus musculus	254-270
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	prostaglandin-endoperoxide synthase 2	Mus musculus	272-277
31669306-6	2020	Finally, using a well-established murine model of DED, topical treatment of DED mice with NK1R antagonists CP-99,994 and L-733,060 suppressed APC acquisition of MHC II, reduced Th17 cell activity, and ameliorated DED severity.	3-(2-methoxybenzylamino)-2-phenylpiperidine	107-116	tachykinin receptor 1	Mus musculus	90-94
31669306-6	2020	Finally, using a well-established murine model of DED, topical treatment of DED mice with NK1R antagonists CP-99,994 and L-733,060 suppressed APC acquisition of MHC II, reduced Th17 cell activity, and ameliorated DED severity.	3-(2-methoxybenzylamino)-2-phenylpiperidine	107-116	histocompatibility-2, MHC	Mus musculus	161-167
28464353-0	2017	Neurokinin-1 receptor blocker CP-99 994 improved emesis induced by cisplatin via regulating the activity of gastric distention responsive neurons in the dorsal motor nucleus of vagus and enhancing gastric motility in rats.	3-(2-methoxybenzylamino)-2-phenylpiperidine	30-39	tachykinin receptor 1	Rattus norvegicus	0-21
28833499-3	2018	This effect was nullified by pretreatment of the neurokinin-1 receptor (NK-1R) antagonist CP99994.	3-(2-methoxybenzylamino)-2-phenylpiperidine	90-97	tachykinin receptor 1	Mus musculus	49-70
28833499-3	2018	This effect was nullified by pretreatment of the neurokinin-1 receptor (NK-1R) antagonist CP99994.	3-(2-methoxybenzylamino)-2-phenylpiperidine	90-97	tachykinin receptor 1	Mus musculus	72-77
28464353-3	2017	This study aimed to examine the role of NK1 receptor blocker, CP-99 994, when administrated into dorsal motor nucleus of vagus (DMNV), on the cisplatin-induced emesis in rats and the possible mechanism.	3-(2-methoxybenzylamino)-2-phenylpiperidine	62-71	tachykinin receptor 1	Rattus norvegicus	40-52
29269174-10	2018	All of these effects were completely reversed by co-treatment with the NK1R antagonist CP99994.	3-(2-methoxybenzylamino)-2-phenylpiperidine	87-94	tachykinin receptor 1	Mus musculus	71-75
22927867-7	2012	Administration of CP-99994, an antagonist of the neurokinin (NK)1 receptor, attenuates the SS exposure-enhanced tracheal smooth muscle responses to EFS.	3-(2-methoxybenzylamino)-2-phenylpiperidine	18-26	tachykinin receptor 1	Mus musculus	49-74
20615399-7	2010	In sigmoid circular muscle, neurotensin responses were also enhanced by TTX and hexamethonium, but were attenuated in the presence of mepyramine, MEN10627 and CP99994, suggesting inhibitory neuronal mechanisms and involvement of histamine and tachykinins, respectively; L-NAME and the GABA(B) receptor antagonist, CGP36742, were without effect.	3-(2-methoxybenzylamino)-2-phenylpiperidine	159-166	neurotensin	Homo sapiens	28-39
16825299-5	2006	Pretreatment with the NK1R antagonist CP99994 in the BotC significantly attenuated the bradypnoeic response to SSP injection and blunted the increase in T(E) duration.	3-(2-methoxybenzylamino)-2-phenylpiperidine	38-45	tachykinin receptor 1	Rattus norvegicus	22-26
19164461-9	2009	The restoration by indomethacin was blocked by the NK(1) receptor antagonist CP99994 [(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine] and TTX.	3-(2-methoxybenzylamino)-2-phenylpiperidine	77-84	tachykinin receptor 1	Homo sapiens	51-65
19164461-9	2009	The restoration by indomethacin was blocked by the NK(1) receptor antagonist CP99994 [(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine] and TTX.	3-(2-methoxybenzylamino)-2-phenylpiperidine	86-137	tachykinin receptor 1	Homo sapiens	51-65
18480245-8	2008	The neurokinin-1 (NK1) receptor antagonist CP-99,994 (10 mM) abolished cough responses, whereas the NK2 receptor antagonist MEN 10376 (5 mM) had no effect.	3-(2-methoxybenzylamino)-2-phenylpiperidine	43-52	tachykinin receptor 1	Homo sapiens	4-31
16239038-5	2006	Different doses of substance P receptor (NK1R) antagonist CP 99994 were administered peripherally or centrally before the stress exposure.	3-(2-methoxybenzylamino)-2-phenylpiperidine	58-66	tachykinin receptor 1	Rattus norvegicus	19-39
16239038-5	2006	Different doses of substance P receptor (NK1R) antagonist CP 99994 were administered peripherally or centrally before the stress exposure.	3-(2-methoxybenzylamino)-2-phenylpiperidine	58-66	tachykinin receptor 1	Rattus norvegicus	41-45